Presbia PLC (LENS) Receives Daily News Impact Rating of 0.27

News stories about Presbia PLC (NASDAQ:LENS) have trended positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Presbia PLC earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 45.725381577338 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several research firms have recently weighed in on LENS. Zacks Investment Research lowered shares of Presbia PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, May 24th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Presbia PLC in a research note on Tuesday, May 23rd. Finally, Rodman & Renshaw lowered their price objective on shares of Presbia PLC from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $12.00.

Shares of Presbia PLC (LENS) traded up 1.11% during mid-day trading on Friday, hitting $2.46. 16,165 shares of the company traded hands. The firm has a 50-day moving average of $2.34 and a 200-day moving average of $2.81. The stock’s market capitalization is $41.71 million. Presbia PLC has a one year low of $1.86 and a one year high of $5.07.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was first published by [[site]] and is owned by of [[site]]. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at [[permalink]].

About Presbia PLC

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.